ORGANIGRAM GLOBAL (OGI) Company Report

Analyst Coverage

Research analysts who have asked questions during ORGANIGRAM GLOBAL earnings calls.

Alliance Global Partners

3 questions for OGI

ATB Capital Markets

3 questions for OGI

Canaccord Genuity

3 questions for OGI

Zuanic & Associates

1 question for OGI

Recent press releases and 8-K filings for OGI.

Organigram Global Inc. expands innovation investment with Phylos Bioscience Inc.

OGI

New Projects/Investments

Debt Issuance

Organigram Global Inc. (OGI) has expanded its innovation investment in Phylos Bioscience Inc., securing enhanced operational security, priority access to selected genetics, and a robust seed pipeline through 2030.
The agreement includes the delivery of 30 new, next-generation genetics twice annually through 2030.
Organigram has secured five-year exclusive rights for its chosen autoflower cultivars in international markets such as Canada, Australia, the UK, Germany, and Israel, with the option to add new territories.
Under the amended loan agreement, Organigram will make a US$3 million advance, bringing the total loan principal to US$10 million, which matures on May 25, 2028.

Dec 31, 2025, 2:49 PM

Organigram Global Reports Record Q4 and Full Fiscal Year 2025 Results with Strong 2026 Outlook

OGI

Earnings

Guidance Update

Revenue Acceleration/Inflection

Organigram Global reported record net revenue of CAD 80.1 million in Q4 2025, a 79% increase year-over-year, and CAD 259.2 million for the full fiscal year 2025, up 62% from the prior year. The company also achieved its highest adjusted gross margin of 38% in Q4 2025 and record adjusted EBITDA of CAD 9.8 million.
The company maintained its number one market share position in Canada with 11.9% in fiscal 2025, with three brands among the top 10 cannabis brands by retail sales.
International sales reached a record CAD 26.3 million in fiscal 2025, marking a 171% increase from fiscal 2024, supported by partnerships in Germany and new US hemp-derived product launches.
The Motif Labs acquisition contributed CAD 7.1 million in cost savings in fiscal 2025, with annualized savings expected to exceed CAD 15 million, and the company expects continued operational leverage and margin improvement from cultivation optimization.
For fiscal 2026, Organigram projects continued strong net revenue growth exceeding CAD 300 million, further improvements in adjusted gross margin (approaching 40%) and adjusted EBITDA, and expects to generate free cash flow.

Dec 16, 2025, 1:00 PM

Organigram Reports Record Q4 and Full-Year 2025 Results, Provides Strong 2026 Guidance

OGI

Earnings

Guidance Update

Revenue Acceleration/Inflection

Organigram (OGI) reported record Q4 2025 net revenue of CAD 80.1 million, a 79% increase year-over-year, and record full-year 2025 net revenue of CAD 259.2 million, up 62% from the prior year.
The company achieved a record Q4 adjusted gross margin of 38% and record full-year adjusted EBITDA of CAD 21.9 million in fiscal 2025, representing a 160% increase from fiscal 2024.
OGI maintained its number one market position in Canada with 11.9% market share in fiscal 2025 and delivered record international sales of CAD 26.3 million, a 171% increase from fiscal 2024.
The Motif Labs acquisition contributed approximately CAD 7.1 million in cost savings in fiscal 2025, with annualized savings expected to exceed CAD 15 million.
For fiscal 2026, Organigram projects net revenue to exceed CAD 300 million, with further improvements in adjusted gross margin (approaching 40%) and adjusted EBITDA, and expects to generate free cash flow.

Dec 16, 2025, 1:00 PM

Organigram Global launches new U.S. hemp-derived THC brand happly

OGI

Product Launch

New Projects/Investments

Organigram Global Inc. (OGI) launched happly, its third U.S. hemp-derived delta-9 brand, on October 9, 2025.
The happly brand introduces vegan, hemp-derived gummies with targeted formulations for Socialize, Relax, and Sleep mood states, incorporating functional ingredients like caffeine, l-theanine, and chamomile extract.
happly is Organigram's first U.S. brand to feature proprietary FAST™ nanoemulsion technology, designed for more consistent and predictable effects.
The product will initially be sold direct-to-consumer in 23 U.S. states, with retail expansion anticipated later in the year.